Stockreport

bluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent ß-Thalassemia and Sickle Cell Disease at 60th Annual Meeting of the American S...

bluebird bio, Inc.  (BLUE) 
Last bluebird bio, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.bluebirdbio.com/investor-overview
PDF All patients with transfusion-dependent ß-thalassemia and a non-ß0/ß0 genotype who achieved transfusion independence continue to maintain it for up to 3. [Read more]